Type 2 diabetes mellitus: limitations of conventional therapies and intervention with nucleic acid-based therapeutics.
†School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Brisbane, QLD 4102, Australia.
Ganesh R
GR
Kokil
§Center for Comparative Genomics, Murdoch University, 90 South Street, Murdoch, WA 6150, Australia.|∥Western Australian Neuroscience Research Institute, Perth, WA 6150, Australia.|‡School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane QLD 4072 Australia.
Rakesh N
RN
Veedu
⊥The Hepatic Fibrosis Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.|#Faculty of Medicine and Biomedical Sciences, The University of Queensland, Brisbane, QLD 4006, Australia.
Grant A
GA
Ramm
∇Mater Research Institute, The University of Queensland, Brisbane, QLD 4101, Australia.
Johannes B
JB
Prins
†School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Brisbane, QLD 4102, Australia.
Harendra S
HS
Parekh
D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007333:Insulin Resistance; D009696:Nucleic Acids / Q000627:therapeutic use*; D034622:RNA Interference
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D009696:Nucleic Acids